- Home
- API vs CLLS Comparison
API vs CLLS Comparison
Compare API & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | API | CLLS |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 386.2M | 384.3M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | API | CLLS |
|---|---|---|
| Price | $3.94 | $4.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | ★ 324.5K | 36.3K |
| Earning Date | 05-26-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.74 | N/A |
| Revenue Next Year | $12.60 | $0.62 |
| P/E Ratio | $92.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.54 | $1.33 |
| 52 Week High | $5.15 | $5.48 |
Technical Indicators
Market Signals| Indicator | API | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 58.03 | 65.40 |
| Support Level | $3.72 | $3.25 |
| Resistance Level | $4.03 | $4.46 |
| Average True Range (ATR) | 0.12 | 0.22 |
| MACD | 0.07 | 0.12 |
| Stochastic Oscillator | 76.82 | 79.09 |
Price Performance
Historical ComparisonAbout API Agora Inc.
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.